Relay Therapeutics, Inc. (NASDAQ: RLAY) is capturing the attention of investors with its substantial 65.91% potential upside, according to recent analyst ratings. As a clinical-stage precision medicines company, Relay Therapeutics is at the forefront of transforming drug discovery, making significant strides in the realm of targeted oncology and genetic diseases.

With a market capitalization of $1.54 billion, Relay Therapeutics is a notable player in the healthcare sector, specifically within the biotechnology industry. The company’s innovative approach to drug discovery, particularly its focus on small molecule therapeutics, positions it as a leader in targeting oncology and genetic disease indications.

Currently trading at…